Overall, several strategies to block CXCL12/CXCR4 signaling in breast cancer have been proposed including PPAR-γ agonists, dimerization with other receptors or chemokines and specific CXCR4 inhibitors including AMD3100. This evidence concerns the gene CXCR4 and breast cancer.